BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21264845)

  • 21. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
    Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
    Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
    Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
    Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan Z; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Cancer Sci; 2019 Oct; 110(10):3368-3374. PubMed ID: 31432574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
    Liu X; Wang Y; Cao K; Yao L; Hu L; Sun J; Zhang J; Xu Y; Xie Y
    Breast Cancer Res Treat; 2023 May; 199(1):25-33. PubMed ID: 36930346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
    Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
    J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
    Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
    Hubert A; Mali B; Hamburger T; Rottenberg Y; Uziely B; Peretz T; Kadouri L
    Fam Cancer; 2009; 8(3):173-7. PubMed ID: 19016350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
    Wang C; Zhang J; Wang Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2015 Mar; 26(3):523-8. PubMed ID: 25480878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
    Phillips KA; Nichol K; Ozcelik H; Knight J; Done SJ; Goodwin PJ; Andrulis IL
    J Natl Cancer Inst; 1999 Mar; 91(5):469-73. PubMed ID: 10070948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    Pearson EJ; Nair A; Daoud Y; Blum JL
    Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.